Personal Statement
I have a passion for improving the medicines that are given to babies and children.
We have studied more than 15 medicines given to premature babies and examined methods to evaluate drug safety, medicines administration and the costs of off-label medicines.
This experience has led me to work with regulators, pharmaceutical and research networks in the UK, Europe and globally to improve the way we do research that involves children.
I am currently serving as CEO of a Dutch non-profit that operates a European paediatric clinical research network (conect4children.eu)


Clinical Academic / Consultant Neonatologist.
BSc (St. Andrews); MBChB, PhD (Manchester);
CCST in Paediatrics / Neonatal medicine (Clinical training, Liverpool / Manchester)

Research Overview
My research aims to improve the access of newborn babies and children to high quality medicines. This has included studies of dosing, safety, and efficacy of 15 medicines (contributing to writing 5 paediatric investigation plans); excipient kinetics; manipulations of medicines; the assessment of adverse drug reactions; and the value of age-appropriate formulations.

I believe that the coherent integration of the design and conduct of clinical trials is key to improving the quality of medicines. He works to develop efficient medicines research infrastructure in Europe and globally as Chair of the European Network for Paediatric Research at the European Medicines Agency (EnprEMA) (2013 – 2019), Convenor of the European Paediatric Clinical Trials Research Infrastructure, co-Director of the International Neonatal Consortium and as co-Coordinator of the Collaborative Network for European Clinical Trials For Children (conect4children, c4c), now CEO of the non-profit that will sustain the work of c4c.